Coherus BioSciences Inc (CHRS)
1.90
-0.22
(-10.38%)
USD |
NASDAQ |
May 10, 16:00
1.91
+0.01
(+0.53%)
After-Hours: 20:00
Coherus BioSciences Enterprise Value: 571.27M for May 10, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 10, 2024 | 571.27M |
| May 09, 2024 | 596.24M |
| May 08, 2024 | 608.72M |
| May 07, 2024 | 610.99M |
| May 06, 2024 | 607.59M |
| May 03, 2024 | 613.26M |
| May 02, 2024 | 601.91M |
| May 01, 2024 | 589.43M |
| April 30, 2024 | 578.08M |
| April 29, 2024 | 590.56M |
| April 26, 2024 | 587.16M |
| April 25, 2024 | 574.67M |
| April 24, 2024 | 584.89M |
| April 23, 2024 | 603.05M |
| April 22, 2024 | 603.05M |
| April 19, 2024 | 590.56M |
| April 18, 2024 | 582.62M |
| April 17, 2024 | 599.64M |
| April 16, 2024 | 599.64M |
| April 15, 2024 | 605.32M |
| April 12, 2024 | 608.72M |
| April 11, 2024 | 629.15M |
| April 10, 2024 | 633.69M |
| April 09, 2024 | 635.96M |
| April 08, 2024 | 638.53M |
| Date | Value |
|---|---|
| April 05, 2024 | 629.52M |
| April 04, 2024 | 618.25M |
| April 03, 2024 | 623.88M |
| April 02, 2024 | 621.63M |
| April 01, 2024 | 626.14M |
| March 28, 2024 | 625.01M |
| March 27, 2024 | 628.39M |
| March 26, 2024 | 614.86M |
| March 25, 2024 | 612.61M |
| March 22, 2024 | 618.25M |
| March 21, 2024 | 638.53M |
| March 20, 2024 | 635.15M |
| March 19, 2024 | 631.77M |
| March 18, 2024 | 605.85M |
| March 15, 2024 | 605.85M |
| March 14, 2024 | 600.21M |
| March 13, 2024 | 614.86M |
| March 12, 2024 | 608.10M |
| March 11, 2024 | 611.48M |
| March 08, 2024 | 625.01M |
| March 07, 2024 | 604.72M |
| March 06, 2024 | 604.72M |
| March 05, 2024 | 601.34M |
| March 04, 2024 | 611.48M |
| March 01, 2024 | 627.26M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
518.77M
Minimum
Nov 10 2023
1.692B
Maximum
Jul 03 2019
1.027B
Average
1.033B
Median
Aug 18 2021
Enterprise Value Benchmarks
| AbbVie Inc | 339.84B |
| Inovio Pharmaceuticals Inc | 120.37M |
| Nektar Therapeutics | 19.56M |
| Avid Bioservices Inc | 661.08M |
| Stereotaxis Inc | 164.80M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -79.65M |
| Revenue (Quarterly) | 91.52M |
| Total Expenses (Quarterly) | 160.43M |
| EPS Diluted (Quarterly) | -0.74 |
| Gross Profit Margin (Quarterly) | 7.60% |
| Profit Margin (Quarterly) | -87.03% |
| Earnings Yield | -136.8% |
| Normalized Earnings Yield | -136.84 |